DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors

WILMINGTON, Mass., May 13 /PRNewswire-FirstCall/ — DUSA
Pharmaceuticals, Inc.^® (Nasdaq: DUSA), a dermatology company that is developing
and marketing Levulan^® Photodynamic Therapy (PDT)
and other products focused on patients with common skin conditions,
today announced that its Annual Meeting of Shareholders will be
held on Thursday, July 29, 2010 at
11:00 AM at the Company’s offices at
25 Upton Drive, Wilmington, MA.
 The Company also reported that it has nominated a slate of
directors for election at the annual meeting, namely, Jay M. Haft, Esq., Chairman, Alfred Altomari, David M. Bartash, Alexander W. Casdin, Robert F. Doman, Paul Hondros, Magnus Moliteus and David M. Wurzer. The nomination of David M. Wurzer is being made as a result
of the resolution of the Company’s discussions with SRB Greenway
Opportunity Fund, (QP), L.P. and SRB Greenway Opportunity Fund,
L.P., and several affiliates (“SRB Funds”). A full copy of the
agreement with the SRB Funds dated May 13,
2010 will be filed as an exhibit to the Company’s Form 8-K
being filed contemporaneously with this announcement.

“We are excited to propose such a strong slate of directors,
which includes several new nominees.  We believe their
experience, successful track records and demonstrated corporate
leadership will greatly benefit the Company and its shar

‘/>”/>

SOURCE